Chong Kun Dang Pharmaceutical
As of the edition of 20 October 2026, Chong Kun Dang Pharmaceutical runs 87 drugs, 4 of them marketed; it is on route A at 1 target and on route B at 2 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 4 |
| Active | 11 |
| Went quiet | 37 |
| Stopped | 1 |
| Status not established | 34 |
| Total | 87 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Lobeglitazone | none listed | 1 |
| Levamlodipine | none listed | 4 |
| Belotecan | none listed | 1 |
| Choline alfoscerate | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 1 target, route B at 2 targets.
All 3 rows on route A or B
In the product3 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 3 targets where Chong Kun Dang Pharmaceutical needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Nutrition and metabolism: 84 trials led
- Heart and blood vessels: 54 trials led
- Hormones: 48 trials led